ClinicalTrials.gg
WithdrawnNCT05986721Updated May 25, 2025

Clinical Trial of AGB101 for Mild Cognitive Impairment

A Phase 2 interventional study of AGB101 and Placebo in Mild Cognitive Impairment and Prodromal Alzheimer's Disease, sponsored by AgeneBio. Withdrawn at 1 site in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by AgeneBio · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,421 studies in Cognitive Dysfunction with a site in United States — 329 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Enrollment
1,125th of 1,146
0 · median 59
Started
2024
with 94 others
Phase 2
198 of 1,421
37 open now
Registered
1,114th of 1,421
by date

Among the 1,421 studies in Cognitive Dysfunction with a site in United States, this one is the 1,125th largest by enrollment of the 1,146 interventional ones that give a count, is one of 95 that started in 2024, is one of 198 in phase 2, and was the 1,114th registered.

Cognitive Dysfunction

3,881 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

329 of the 1,421 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

324 more — sign in →

All 329 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,421 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by reduction in neuronal injury in participants with mild cognitive impairment due to Alzheimer's Disease. Participants will be randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by the Clinical Dementia Rating Scale- Sum of Boxes and Memory Box score.

Read the detailed description

AGB101 is hypothesized to slow the progression of MCI due to AD by restoring the entorhinal/hippocampal network balance. During this phase of the disease, fMRI studies show hippocampal over-activity and EC under-activity. As shown in the phase 2 study, AGB101 restores this network balance by attenuating hippocampal over-activity and restoring EC activity. Hippocampal over-activity predicts progression on EC atrophy (primary endpoint) and on CDR-SB (secondary endpoint). By restoring network balance, AGB101 is hypothesized to improve cognitive function (CDR-SB) and reduce neuronal injury (EC atrophy).

03

Conditions studied

  • Mild Cognitive Impairment
  • Prodromal Alzheimer's Disease
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects between 55 and 85 years old (inclusive) in good general health:

    1. Willing and able to consent and participate for the duration of the study.
    2. Have eighth-grade education or good work history sufficient to exclude mental retardation.
    3. Have visual and auditory acuity adequate for neuropsychological testing.
    4. Have proficient fluency of the native local language to participate in all the neuropsychological test assessments.
  2. Have a study partner who has sufficient contact with the subject to be able to provide assessment of memory changes, who can accompany the subject to the screening visit and all major clinic visits for the duration of those visits, and who is able to provide an independent evaluation of the subject's functioning.
  3. Have MCI as defined by all of the following criteria and consistent with the National Institute on Aging-Alzheimer's Association criteria:

    1. scores between 24 and 30 (inclusive; exceptions may be made for subjects with \<8 years of education at the discretion of the sponsor).
    2. A memory complaint reported by the subject or his/her study partner.
    3. Evidence of lower memory performance based on the delayed recall portion on a list learning task (ISLT or BSRT).
    4. A CDR score of 0.5 with a memory box score of ≥ 0.5.
    5. Essentially preserved activities of daily living.
    6. Cognitive decline not primarily caused by vascular, traumatic, or medical problems (alternative causes of cognitive decline are ruled out).
  4. Have an Apolipoprotein E (ApoE) genotype that does not include one or more E4 alleles.
  5. Permitted medications:

    1. With potential pro-cognitive effects, such as cholinesterase inhibitors and memantine, must be at a stable dose for ≥ 3 months prior to screening and expected to remain stable throughout the study; estrogen replacement therapy, Ginkgo biloba, and vitamin E must be at a stable dose for ≥ 4 weeks prior to screening and expected to remain stable throughout the study.
    2. Other psychotropics, such as antidepressants and antipsychotics, must be at a stable dose for ≥ 3 months prior to screening and expected to remain stable throughout the study.
  6. Willing and able to undergo imaging procedures:

    1. An amyloid-imaging PET scan with 11C-PiB or documented evidence of an amyloid-positive PET scan.

      The amyloid PET scan performed at baseline must be read by a qualified physician with experience in reading amyloid PET scans, and it should be consistent with the presence of amyloid plaques.

    2. Repeated MRI scans (3 Tesla) with no to MRI. The MRI scan performed at baseline must be read by a physician with experience in evaluating brain-imaging studies in dementia. MRI scan results are consistent with the diagnosis of amnestic MCI due to AD with no findings of non-AD pathology that could account for the observed cognitive impairment.
  7. Willing to allow collection of blood for apolipoprotein E (ApoE) genotyping and banking.

Exclusion criteria

Exclusion Criteria:

  1. Carrying one or more copies of the apolipoprotein E4 (ApoeE4) allele.
  2. Use of anticonvulsant medications or excluded psychotropic medications within 3 months prior to the baseline visit.
  3. Use of anti-amyloid medications at any time prior to screening visit, or at any time during the study.
  4. Participation in a therapeutic clinical study for any medical or psychiatric indications within 3 months (6 months for biologics) of the screening visit, or at any time during the study. Subjects must understand that they may only enroll in this clinical study once; they may not enroll in any other clinical study while participating in the current study, and they may not participate in a clinical study of a drug, biologic, therapeutic device, or medical food, in which the last dose/administration was received within 3 months (6 months for biologics) prior to screening.
  5. History of or lack of tolerability to AGB101 (levetiracetam).
  6. Severe renal impairment ( of \< 30 mL/minute) or undergoing hemodialysis.
  7. Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder (lifetime history; infant febrile seizures are not exclusionary), subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities.
  8. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body that constitute a to having an MRI.
  9. Diagnosis of bipolar disorder, or major depression within the past 3 years, as described in the . Psychotic features, agitation, or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol. Subjects must not have a major depressive disorder or other types of depression that could confound diagnosis of MCI due to AD, or clinical assessments, in the opinion of the investigator. The Geriatric Depression Scale [GDS] (long form score > 9 suggests depression) results should be reviewed by the investigator to assist in this determination.
  10. Modified Hachinski Ischemic Scale (HIS) score > 4.
  11. History of schizophrenia (DSM-5 criteria).
  12. History of alcohol or substance abuse or dependence within the past 3 years (DSM-5 criteria).
  13. Any significant systemic illness or unstable medical condition that could lead to difficulty in complying with the protocol requirements.
  14. Any unstable medical condition that is likely to require new medical or surgical treatment during the course of the study and where such treatments might affect the collection of efficacy data.
  15. abnormalities in B12 or thyroid function test that might interfere with the study. A low B12 (below normative range for elderly) is exclusionary, unless follow-up labs (homocysteine and methylmalonic acid) indicate that it is not physiologically significant. If the B12 deficiency is treated, subjects may become eligible to participate in the study.
  16. Residence in a skilled nursing facility. Individuals in independent living communities, assisted living facilities, residential care facilities, or continuing care communities are eligible provided they engage in a sufficient spectrum of activity to permit assessment of all 6 domains contributing to the CDR-SB. Individuals in these facilities must also have a study partner who has the ability to observe the subject during the study and can participate in clinical evaluations.
  17. Any use of excluded medications (eg, antiepileptics, certain antidepressants or antipsychotics, antihistamines with anticholinergic properties, opiates).
  18. Participation in clinical studies using the ISLT/BSRT, BPS-O task, or the trail making test (A, B) within 1 month of screening.
  19. Female subjects must not be pregnant, lactating, or of (ie, they must be 2 years or surgically sterile).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo Oral Tablet

    Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks

    Drug: Placebo

  • Experimental
    AGB101 220 mg tablet

    Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.

    Drug: AGB101

Interventions

  • DrugAGB101

    low-dose levetiracetam, 220 mg, extended release tablet

    Also known as: levetiracetam, keppra

  • DrugPlacebo

    Placebo oral tablet

    Also known as: placebo tablet

06

What researchers measure

Primary outcomes

  1. Change in Entorhinal Cortex (EC) Volume From Baseline

    Magnetic resonance imaging (MRI) will be used to assess neuronal injury via change in EC volume from baseline to 78 weeks. Negative change scores indicate reduced volume at 78 weeks and positive change scores indicate increase in volume at 78 weeks. Greater numbers therefore correspond with better outcomes.

    Time frame: 78 weeks

Secondary outcomes

  1. Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline

    CDR-SB scores at baseline will be subtracted from CDR-SB scores at week 78 to generate the change score from baseline, with a possible total range of -18 to 18. Positive change scores reflect greater impairment on the CDR-SB at week 78, while negative change scores reflect less impairment on the CDR-SB at week 78.

    Time frame: 78 weeks

  2. Change in Clinical Dementia Rating Scale - Memory Box Score From Baseline

    The CDR- memory box score at baseline will be subtracted from the CDR- memory box score at week 78 to generate the change score from baseline, with a possible total range of -3 to 3. Positive change scores reflect greater impairment on the CDR-SB at week 78, while negative change scores reflect less impairment on the CDR-SB at week 78.

    Time frame: 78 weeks

07

Study locations

1 site
  • Johns Hopkins
    Baltimore, Maryland 21287, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jul 2028, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Aug 14, 2023
StartActual
Dec 3, 2024
Primary completionEst.
Jul 2028
CompletionEst.
Dec 2028
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05986721
Lead sponsor
AgeneBio
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Dec 3, 2024
Primary completion
Jul 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 25, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion